Scientific Reports (Mar 2023)

Modulating heart rate oscillation affects plasma amyloid beta and tau levels in younger and older adults

  • Jungwon Min,
  • Jeremy Rouanet,
  • Alessandra Cadete Martini,
  • Kaoru Nashiro,
  • Hyun Joo Yoo,
  • Shai Porat,
  • Christine Cho,
  • Junxiang Wan,
  • Steve W. Cole,
  • Elizabeth Head,
  • Daniel A. Nation,
  • Julian F. Thayer,
  • Mara Mather

DOI
https://doi.org/10.1038/s41598-023-30167-0
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Slow paced breathing via heart rate variability (HRV) biofeedback stimulates vagus-nerve pathways that counter noradrenergic stress and arousal pathways that can influence production and clearance of Alzheimer's disease (AD)-related proteins. Thus, we examined whether HRV biofeedback intervention affects plasma Αβ40, Αβ42, total tau (tTau), and phosphorylated tau-181 (pTau-181) levels. We randomized healthy adults (N = 108) to use slow-paced breathing with HRV biofeedback to increase heart rate oscillations (Osc+) or to use personalized strategies with HRV biofeedback to decrease heart rate oscillations (Osc−). They practiced 20–40 min daily. Four weeks of practicing the Osc+ and Osc− conditions produced large effect size differences in change in plasma Aβ40 and Aβ42 levels. The Osc+ condition decreased plasma Αβ while the Osc− condition increased Αβ. Decreases in Αβ were associated with decreases in gene transcription indicators of β-adrenergic signaling, linking effects to the noradrenergic system. There were also opposing effects of the Osc+ and Osc− interventions on tTau for younger adults and pTau-181 for older adults. These results provide novel data supporting a causal role of autonomic activity in modulating plasma AD-related biomarkers. Trial registration: NCT03458910 (ClinicalTrials.gov); first posted on 03/08/2018.